GE HealthCare Technologies Beheer

Beheer criteriumcontroles 0/4

De CEO GE HealthCare Technologies is Pete Arduini, benoemd in Dec2022, heeft een ambtstermijn van 1.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 24.51M, bestaande uit 5.1% salaris en 94.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.003% van de aandelen van het bedrijf, ter waarde $ 1.14M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 1.8 jaar.

Belangrijke informatie

Pete Arduini

Algemeen directeur

US$24.5m

Totale compensatie

Percentage CEO-salaris	5.1%
Dienstverband CEO	1.9yrs
Eigendom CEO	0.003%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

From Spin-Off To Standout: GE HealthCare Is Pretty Impressive

Oct 30

GE HealthCare: The Image Of More Upside Is Very Real

Sep 18

Are Investors Undervaluing GE HealthCare Technologies Inc. (NASDAQ:GEHC) By 28%?

Sep 05

GE HealthCare Technologies Inc.'s (NASDAQ:GEHC) Intrinsic Value Is Potentially 100% Above Its Share Price

Apr 25

GE Vernova: An Interesting Stalwart To Ride The Energy Transition

Apr 02

GE HealthCare Technologies: Growth Prospects Remain Encouraging, And Valuation Is Attractive

Mar 25

GE HealthCare Technologies' Roar Higher Isn't Over Yet

Mar 09

GE HealthCare Technologies: Stable Business, But Future Upside Seems Limited

Feb 14

GE HealthCare Q4 Earnings: Growth Lagging The Market

Feb 06

Analyse CEO-vergoeding

Hoe is Pete Arduini's beloning veranderd ten opzichte van GE HealthCare Technologies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$25m	US$1m	US$1b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	US$10m	US$1m	US$2b

Compensatie versus markt: De totale vergoeding ($USD 24.51M ) Pete } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).

Compensatie versus inkomsten: De vergoeding van Pete is het afgelopen jaar met meer dan 20% gestegen.

CEO

Pete Arduini (59 yo)

1.9yrs

Tenure

US$24,510,947

Compensatie

Mr. Peter J. Arduini, also known as Pete, serves as Director of Ge Healthcare since January 2023. He was a Senior Vice President at General Electric Company since January 2022. He has been President and Ch...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Arduini	President	1.9yrs	US$24.51m	0.0028% $ 1.1m
James Saccaro	VP & CFO	1.4yrs	US$10.97m	0.0033% $ 1.3m
Taha Kass-Hout	Chief Science & Technology Officer	1.8yrs	US$13.87m	0.0035% $ 1.4m
Frank Jimenez	VP, General Counsel & Corporate Secretary	1.8yrs	US$7.51m	0.0047% $ 1.9m
George Newcomb	Controller & Chief Accounting Officer	1.9yrs	geen gegevens	0.0012% $ 468.1k
Jahid Khandaker	Chief Information Officer	no data	geen gegevens	geen gegevens
Carolynne Borders	Chief Investor Relations Officer	no data	geen gegevens	geen gegevens
Rana Strellis	Chief Corporate Marketing & Communications Officer	no data	geen gegevens	geen gegevens
Adam Holton	Chief People Officer	less than a year	geen gegevens	geen gegevens
Thomas Westrick	President & CEO of Patient Care Solutions	4.8yrs	geen gegevens	0.0014% $ 548.8k
Kevin O'Neill	President & CEO of Pharmaceutical Diagnostics	no data	geen gegevens	0.0020% $ 803.1k
Roland Rott	President & CEO of Imaging	1.8yrs	geen gegevens	0.0053% $ 2.1m

1.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GEHC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Arduini	President	1.8yrs	US$24.51m	0.0028% $ 1.1m
H. Culp	Chairman	1.8yrs	US$531.65k	0.089% $ 35.7m
Risa Lavizzo-Mourey	Lead Independent Director	1.8yrs	US$456.65k	0.00023% $ 92.8k
Anne Madden	Independent Director	1.8yrs	US$401.61k	0% $ 0
William Stromberg	Independent Director	1.8yrs	US$421.58k	0% $ 0
Rodney Hochman	Independent Director	1.8yrs	US$401.61k	0% $ 0
Lloyd Howell	Independent Director	1.8yrs	US$401.65k	0% $ 0
Tomislav Mihaljevic	Independent Director	1.8yrs	US$401.65k	0% $ 0
Phoebe Yang	Independent Director	1.8yrs	US$401.65k	0% $ 0
Catherine Lesjak	Independent Director	1.9yrs	US$426.65k	0% $ 0

1.8yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GEHC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

GE HealthCare Technologies Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Insider recently sold US$1.6m worth of stock

GE Healthcare Names Adam Holton as Chief People Officer

President & CEO of Imaging notifies of intention to sell stock

GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024

Recent updates

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

GE HealthCare Technologies Inc. Updates Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations

From Spin-Off To Standout: GE HealthCare Is Pretty Impressive

GE HealthCare Technologies Inc. Announces Hospital Pulse, the Newest Tile for Its Command Center Software Platform

GE HealthCare Introduces Easy-To-Use, Easy-To-Learn, Easy-To-Appoint Versana Premier Multi-Purpose Ultrasound System

Upcoming dividend of US$0.03 per share

GE Healthcare Accelerates Artificial Intelligence Adoption with New Offering to Advance Enterprise Imaging

GE HealthCare Technologies Inc. to Report Q3, 2024 Results on Oct 30, 2024

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

GE Healthcare Announces FDA Approval of Flyrcado (Flurpiridaz F 18) Injection Pet Radiotracer for Enhanced Diagnosis of Coronary Artery Disease

Second quarter dividend of US$0.03 announced

GE HealthCare Introduces Elevated Venue Point of Care Ultrasound Solutions and New Tablet-Based Venue Sprint

GE HealthCare: The Image Of More Upside Is Very Real

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

Are Investors Undervaluing GE HealthCare Technologies Inc. (NASDAQ:GEHC) By 28%?

GE HealthCare Technologies Inc. Showcases Latest AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments At the Point of Care At ESC 2024

GE HealthCare Announces the Publication of the MASTER Trial Results in the Peer-Reviewed Journal Anesthesia and Analgesia

Insider recently sold US$1.6m worth of stock

GE HealthCare Q2 Earnings Recap (Rating Downgrade)

Second quarter 2024 earnings: EPS exceeds analyst expectations

GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024

GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q2, 2024 Results on Jul 31, 2024

GE HealthCare: Near-Term Risks, But Some Interesting Longer-Term Opportunities

First quarter dividend of US$0.03 announced

GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of 2024, Payable on August 15, 2024

GE Healthcare Names Adam Holton as Chief People Officer

Is GE HealthCare Technologies (NASDAQ:GEHC) A Risky Investment?

President & CEO of Imaging notifies of intention to sell stock

GE HealthCare Unveils SIGNA MAGNUS, an FDA 510(K) Pending Head-Only Magnetic Resonance (MR) Scanner Designed to Explore Advance Advancements in Neuro Science

GE HealthCare: Too Soon To Buy After A Mixed Q1 (Rating Downgrade)

GE HealthCare Launches New Era of AI-Enhanced, Personalized Oncology Solutions at ESTRO 2024 Congress

First quarter 2024 earnings: EPS and revenues miss analyst expectations

GE HealthCare Technologies Inc. Reaffirms Earnings Guidance for the Full Year 2024

GE HealthCare Technologies Inc.'s (NASDAQ:GEHC) Intrinsic Value Is Potentially 100% Above Its Share Price

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women's Health Imaging

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q1, 2024 Results on Apr 30, 2024

GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024

GE Healthcare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

GE Vernova: An Interesting Stalwart To Ride The Energy Transition

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

GE HealthCare Technologies: Growth Prospects Remain Encouraging, And Valuation Is Attractive

GE HealthCare Technologies Inc. to Feature Latest Technologies in Interventional Radiology Focused on Precision Care At Sir 2024

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

GE HealthCare Technologies' Roar Higher Isn't Over Yet

GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $1.06925 billion.

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

GE HealthCare Technologies: Stable Business, But Future Upside Seems Limited

Price target increased by 7.6% to US$90.21

Full year 2023 earnings: EPS misses analyst expectations

Now 33% overvalued after recent price rise

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Full Year of 2024

GE HealthCare Q4 Earnings: Growth Lagging The Market

GE HealthCare Technologies Inc. Receives 510(K) Clearance from the United States Food and Drug Administration for Novii™+ Wireless Patch Solution

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd